Karl H. Schoenbach

Karl H. Schoenbach

Auto-generated profile, based on publicly available information

Karl H. Schoenbach

Old Dominion University

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 February 2009 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
RNRichard Nuccitelli
Richard Nuccitelli
XCXinhua Chen
Xinhua Chen
Andrei PakhomovAndrei Pakhomov
Andrei Pakhomov
WBWallace H. Baldwin
Wallace H. Baldwin
SSSaleh Sheikh
Saleh Sheikh
KSKarl H. Schoenbach
Karl H. Schoenbach
We have discovered a new, ultrafast therapy for treating skin cancer that is extremely effective with a total electric field exposure time of only 180 μsec. The application of 300 high‐voltage (40 kV/cm), ultrashort (300 nsec) electrical pulses to murine melanomas in vivo triggers both necrosis and apoptosis, resulting in complete tumor remission within an average of 47 days in the 17 animals treated. None of these melanomas recurred during a 4‐month period after the initial melanoma had disappeared. These pulses generate small, long‐lasting, rectifying nanopores in the plasma membrane of exposed cells, resulting in increased membrane permeability to small molecules and ions, as well as an increase in intracellular Ca2+, DNA fragmentation, disruption of the tumor's blood supply and the initiation of apoptosis. Apoptosis was indicated by a 3‐fold increase in Bad labeling and a 72% decrease in Bcl‐2 labeling. In addition, microvessel density within the treated tumors fell by 93%. This new therapy utilizing nanosecond pulsed electric fields has the advantages of highly localized targeting of tumor cells and a total exposure time of only 180 μsec. These pulses penetrate into the interior of every tumor cell and initiate DNA fragmentation and apoptosis while at the same time reducing blood flow to the tumor. This new physical tumor therapy is drug free, highly localized, uses low energy, has no significant side effects and results in very little scarring. © 2009 UICC

1 April 2003 in Biophysical Journal
Verified
Journal Article
Closed access
JDJingdong Deng
Jingdong Deng
KSKarl H. Schoenbach
Karl H. Schoenbach
EBE. Stephen Buescher
E. Stephen Buescher
PHPamela S. Hair
Pamela S. Hair
PFPaula M. Fox
Paula M. Fox
SBStephen J. Beebe
Stephen J. Beebe

1 October 2007 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
AGAllen L. Garner
Allen L. Garner
GCGeorge Chen
George Chen
NCNianyong Chen
Nianyong Chen
VSViswanadham Sridhara
Viswanadham Sridhara
JKJuergen Kolb
Juergen Kolb
KSKarl H. Schoenbach
Karl H. Schoenbach

1 June 2015 in Bioelectrochemistry
Verified
Journal Article
Closed access
KSKarl H. Schoenbach
Karl H. Schoenbach
Andrei PakhomovAndrei Pakhomov
Andrei Pakhomov
ISIurii Semenov
Iurii Semenov
SXShu Xiao
Shu Xiao
OPOlga N. Pakhomova
Olga N. Pakhomova
BIBennett L. Ibey
Bennett L. Ibey


27 September 2010 in Cancers
Verified
Journal Article
Open access
PDF file
SBStephen J. Beebe
Stephen J. Beebe
KSKarl H. Schoenbach
Karl H. Schoenbach
RHRichard Heller
Richard Heller
Two new cancer therapies apply bioelectric principles. These methods target tumor structures locally and function by applying millisecond electric fields to deliver plasmid DNA encoding cytokines using electrogene transfer (EGT) or by applying rapid rise-time nanosecond pulsed electric fields (nsPEFs). EGT has been used to locally deliver cytokines such as IL-12 to activate an immune response, resulting in bystander effects. NsPEFs locally induce apoptosis-like effects and affect vascular networks, both promoting tumor demise and restoration of normal vascular homeostasis. EGT with IL-12 is in melanoma clinical trials and nsPEFs are used in models with B16F10 melanoma in vitro and in mice. Applications of bioelectrics, using conventional electroporation and extensions of it, provide effective alternative therapies for melanoma.